NCT02607813 - Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | Biotech Hunter

Enrollment

142

Participants

Timeline

Start Date

January 18, 2016

Primary Completion Date

February 18, 2022

Study Completion Date

February 19, 2022

Conditions

NSCLCOvarian CancerMelanomaOther Solid Tumors

Interventions

DRUG

LXH254

pan-RAF inhibitor

DRUG

PDR001

Biological: PDR001 anti-PD1 antibody

Trial Locations (18)

8091

Novartis Investigative Site, Zurich

10065

Memorial Sloan Kettering Cancer Center SC - LXH254X2101, New York

20133

Novartis Investigative Site, Milan

28009

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

31059

Novartis Investigative Site, Toulouse

41124

Novartis Investigative Site, Modena

69120

Novartis Investigative Site, Heidelberg

75475

Novartis Investigative Site, Paris

77030

UT M.D Anderson Cancer Center SC - LXH254X2101, Houston

80131

Novartis Investigative Site, Napoli

02114

Massachusetts General Hospital MGH Cancer Center, Boston

M5G 2C1

Novartis Investigative Site, Toronto

104 0045

Novartis Investigative Site, Chuo Ku

9713 GZ

Novartis Investigative Site, Groningen

3075 CE

Medical Oncology, Erasmus MC, Rotterdam

03080

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona